Traws Pharma, Inc.
- TRAW
- NASDAQ
- Biotechnology
- Oral Antivirals
- Oncology (Small Molecule)
- Clinical-Stage Biopharma
$0.37
Today −8.38%Quote Oct 16, 2026, 08:00 PM UTC
−31.04%over the last month
Max drawdown −41.0%From 1-month high −41.0%3 months −39.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$5.7M
Quote Oct 16
Next earnings
Nov 12
Expected, not confirmed
Analyst target
$1.00
+170.8% from here
Floor
$0.34
7.8% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TRAWPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
7